MENLO PARK, Calif., Aug. 31 Transcend Medical, Inc., an ophthalmic device company dedicated to delivering breakthrough advances in the treatment of glaucoma, today announced that it has filled two key positions with the addition of Sean Ianchulev, MD, as Chief Medical Officer and Ginger Clasby as Vice President of Clinical Affairs.
Dr. Ianchulev joins the company from Genentech, Inc where he was the group medical director for the ophthalmology division and the Lucentis franchise. In his role, he headed clinical development and medical affairs activities and was instrumental to the launch and success of Lucentis - a multi-billion dollar bio-therapeutic for the treatment of age-related macular degeneration. Dr. Ianchulev also has deep experience with medical devices. As the founder of the Peristat Group, Inc., he developed the first diagnostic device for remote telemonitoring of visual function and disease management of patients with glaucoma and macular degeneration
Dr. Ianchulev received his medical degree and a master's of public health from Harvard University and completed his specialty training at the Doheny Eye Institute, University of Southern California. As a practicing ophthalmic surgeon and glaucoma specialist, he is well published in the field of ophthalmology and currently serves as an Assistant Clinical Professor of Ophthalmology at the University of California at San Francisco (UCSF).
Ms. Clasby is a seasoned medical device executive with varied, in-depth experience in clinical affairs, operations, quality assurance, and marketing. As an effective leader in both start-ups and large corporate environments, she brings critical knowledge and industry experience gained from more than 15 years serving executive level positions in operations and business development with Promedica International, a contract research organization. At Promedica International, she spearheaded the growth of the clinical regulatory division, establishing the company as a respected, major provider of clinical research services within the ophthalmic and medical device market sectors. Previously she served as Vice President, Marketing and Sales at Optical Radiation Corporation and began her career with nearly a decade of experience at Allergan Medical Optics.
"Ginger and Sean offer us the breadth and depth of relevant experience and leadership skills needed to further develop the Transcend Cypass(TM) System as a therapeutic device to address glaucoma," said Brian Walsh, President and Chief Executive Officer of Transcend Medical. "Their hires come at a critical time of growth as we embark on our pivotal clinical trial."
The Transcend CyPass System is a minimally invasive procedure developed as an alternative or adjunct to chronic, life-long medication therapy for a more effective and convenient treatment for glaucoma. Transcend Medical is validating its novel, proprietary system for the sustained reduction of intraocular pressure (IOP).
About Transcend Medical, Inc.
Transcend Medical (www.transcendmedical.com) focuses on the research and development of medical devices for the treatment of glaucoma, the leading cause of adult irreversible blindness. It is estimated that nearly four million people in the U.S. and 70 million worldwide are afflicted with the disease today and the numbers are expected to grow to nearly six million in the U.S. and to over 80 million worldwide by the year 2013. Based in Menlo Park, Calif., Transcend Medical was the first company to be spun out of ForSight Labs (www.forsightlabs.com), an incubator solely focused on ophthalmic innovations.
SOURCE Transcend Medical, Inc.